NEW YORK, Feb. 17 (GenomeWeb News) - Exelixis today reported an increase in revenues for the quarter ended Dec. 31, 2003, along with higher net losses and rising R&D expenses.

Exelixis posted total revenues of $13.8 million for the fourth quarter, up from $12.5 million in the same period of 2002.

The company's net loss widened to $23.3 million from $20.9 million in the fourth quarter of 2002.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.